health
Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001 Civitas Building, c/o Struben and Thabo Sehume Streets
Tel (012) 395 8000, Fax (012) 395 8918

Mr E Van Zyl
Equity Pharmaceuticals
100 Sovereign Road
Route 21 Corporate Park
Nellmapius Drive
Irene
Pretoria

Dear Mr Van Zyl

Section 21 Authorisation for CISPLATIN 10MG/10ML INJECTION

Attached, please find the Authorisation for exemption under Section 21 of the Medicines and Related Substances Act by SAHPRA granted for:

- **Cisplatin 10mg/10ml Injection**

The quantities for which approval was granted are only estimates based on procurement by provinces over the last 6 months. Please note that the National Department of Health (NDOH) cannot guarantee the procurement of these quantities, as NDOH has no control over orders being placed by provincial depots, and current stock holding might influence estimated quantities.

The following process will be followed to ensure the quality of the product being brought in:

1. Manufacturer will submit an assay and identification of every batch imported.
2. An additional assay of every batch will be done by a quality control laboratory.
3. A random sample will be assayed during the authorized period by a quality control laboratory.
4. Aggregate statistics to be submitted to NDOH in the first week of each month of all orders received and quantities supplied per province.
5. The NDOH needs to be advised of the quantities and date of arrival of stocks in terms of this authorisation within 7 days after arrival.

6. The supplier will provide monthly reports, by the 7th of each month, using the attached format of orders received and issues done.
7. Participating Authorities (PAs) will provide a consolidated close out report of usage using the attached format on the date when an authorisation lapses.
8. The full quantities imported in terms of this Section 21authorisation must be accounted for.
9. Note that this authorisation DOES NOT cover supplies to the private sector.
10. Where this authorisation is obtained to provide security of supply due to supply challenges from the contracted supplier, PAs are requested to buy out against contracted suppliers and ensure that related orders are cancelled accordingly to prevent over stocking once the contracted supplier gets back into stock.

It should be noted this authorisation applies only for use of these products in the public sector with estimated usage quantities for a period of 6 months up until **13 February 2021.**

See below table with provincial estimates.

Province	**Six Months Estimate re Cisplatin 10mg INJ**
Correctional Services	0
EC-MT	0
EC-PE	
FS	0
GP	0
KZN	0
LP	0
MP	300
NC	100
NW	0
South African Military Services	4
WC	50

Kind Regards

K Jamaloodien

KHADIJA JAMALOODIEN

DIRECTOR: AFFORDABLE MEDICINES

DATE: 24/8/2020

SAHPRA
SOUTH AFRICAN
HEALTH PRODUCTS
REGULATORY AUTHORITY

Section 21 Authorization Letter

13/08/2020

Khadija Jamaloodien

222 Thabo Sehume Street; Civitas Building; National Department of Health; Affordable Medicines; Pretoria

Dear Khadija Jamaloodien,

REQUEST TO USE UNREGISTERED MEDICINE IN TERMS OF SECTION 21 OF THE MEDICINES AND RELATED SUBSTANCES CONTROL ACT, 1965 (ACT 101 OF 1965):

Your application dated 13/08/2020 refers

A. ***STATUS:*** *approved*
B. ***APPLICANT:*** Khadija Jamaloodien
C. ***IMPORTING COMPANY:*** Equity Pharmaceuticals (Pty) Ltd
D. ***PATIENT/(S):***
E. ***UNREGISTERED MEDICINES:***
GENERIC NAME: Cisplatin 10mg/10ml Injection
TRADE NAME: Platol 10mg/10ml Injection
QUANTITY: Cisplatin 10mg/10ml Injection x 460 vials
F. ***LETTER NUMBER:*** *OS20543*

Section 21 authorization letters are valid for a period of six months from the letter date, unless otherwise specified.

Comments: -

Yours faithfully,

Dr S Munbodh
Manager: Section 21 Category A Medicines

health
Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001, Civitas Building, Cnr Thabo Sehume & Struben Streets, PRETORIA, 0001
Directorate: Affordable Medicines
Tel: (012) 395 8130, Fax: (012) 395 8823/4

REQUEST FOR QUOTATION FORM

- **Instruction to complete this Request for Quotation (RFQ)**
  PLEASE PROVIDE A QUOTE FOR THE FOLLOWING PRODUCT(S).
  PLEASE QUOTE ON THIS RFQ FORM OR ATTACH YOUR QUOTE WITH THE REQUESTED DETAILS.
  THE SECTIONS HIGHLIGHTED IN YELLOW MUST BE COMPLETED BY THE SUPPLIER.
- **THIS DOES NOT CONSTITUTE ANY OBLIGATION TO PROCURE THE ITEM AS THIS WILL BE SUBMITTED FOR CONSIDERATION TO PROVINCIAL PROCUREMENT UNITS TO SERVE AS A BUY OUT AGAINST CURRENT NON-COMPLIANT SUPPLIERS.**

ONLY RESPONSES FROM DULY REGISTERED SUPPLIERS WILL BE EVALUATED

REFERENCE NUMBER:	NORMAL		SECTION 21	X	**S21RFQ86**
QUOTE ENQUIRY DATE	**22/07/2020**	QUOTE CLOSING DATE			**30/07/2020**
FOR CRITICAL DELIVERY, DELIVERY REQUESTED ON/BEFORE *(SCM Practitioner to Specify if applicable)*					

REQUESTING INSTITUTION CONTACT DETAILS

NAME OF REQUESTOR	Buhle Mbongo		
EMAIL ADDRESS	Buhle.Mbongo@health.gov.za		
PHONE No.	**012 395 9539**	FAX No.	**N/A**

PRODUCT INFORMATION

DESCRIPTION PER MPC	**Cisplatin 10mg Injection**		
TRADE DESCRIPTION	Platol 10mg		
UNIT OF MEASURE	**1**	PACK or BOX *(SIZE/ QUANTITY)*	**1's**
QUANTITY REQUIRED	**460**		

TO BE COMPLETED BY THE SUPPLIER/ SERVICE PROVIDER

SUPPLIER CONTACT DETAILS (as per CSD)

COMPANY NAME	Equity Pharmaceuticals			
SUPPLIER NUMBER				
SECURITY CODE				
SUPPLIER CODE (NDoH)				
CONTACT PERSON 1	NAME	**Ehrard van Zyl**		
	PHONE	**012 345 1747**	FAX	**012 345 1412**
	MOBILE	*072 040 8511*		
	E-MAIL	**ehrard@equitypharma.co.za**		
CONTACT PERSON 2	NAME	**Jaco Schoeman**		
	PHONE	**012 345 1747**		

	MOBILE	*076 734 0080*
	E-MAIL	**jacos@equitypharma.co.za**

QUOTE DETAILS			
PRICE PER UNIT (INCL. VAT)	R 65.55	TOTAL PRICE (INCL. DELIVERY & VAT)	R 30 153.00
VOLUMES AVAILABLE – 14DAYS	460		
VOLUMES AVAILABLE – 28DAYS			
VOLUMES AVAILABLE – 56DAYS			
VOLUMES AVAILABLE – 112DAYS			
QUOTE VALIDITY PERIOD	180 days		
NORMAL LEAD/DELIVERY TIME	3 days		

DEVIATION TO SPECIFICATION
COMMENTS:

DECLARATION BY SUPPLIER	
I hereby declare that in submitting this bid, there has been no consultation, communication, agreement or arrangement with any competitor/supplier regarding the price, quality, quantity, specifications and conditions or delivery particulars of the products or services to which this bid invitation relates.	
NAME	**Ehrard van Zyl**
CAPACITY	**Business Unit Manager: Specialist Medicine**
SIGNATURE *(OF A DULY AUTHORISED REPRESENTATIVE OF THE SUPPLIER)*	
DATE	**30/07/2020**

Please submit quotations to Buhle.Mbongo@health.gov.za

Please ensure that you include the following as part of the Quotation:

- Delivery Time (Weeks)
- Price (Vat Inclusive)
- Generic Name
- Trade Name
- Packaging
- *Package Insert: (Please attach)
- *Manufacturer Certificate: (Please attach)
- *Country of Origin: (Please indicate)

*Required when submitting a quote for a Section 21 Item (Unregistered Medicine)

All of the above is required to expedite the process in considering the quotation.

Please ***SUBMIT QUOTATIONS ON AN OFFICIAL COMPANY LETTERHEAD***

EQUITY
PHARMACEUTICALS

30/07/2020

Equity Pharmaceuticals (Pty) Ltd.
1997/009942/07

+27 12 345 1747
+27 12 345 1412
equity@equitypharma.co.za

www.clinigengroup.com
www.equitypharma.co.za

QUOTATION # 20200730

TO: National Department of Health

TEL: 012 395 9539
FAX:
Email: Buhle.Mbongo@health.gov.za

CONTACT PERSON / PATIENT: Buhle Mbongo

NB IMPORTED AND SUPPLIED UNDER SECTION 21 TERMS

PRODUCT CODE	DESCRIPTION	PACK SIZE	QUANTITY	PRICE EXCL	TOTAL INCL
	Platol (Cisplatin) 10mg	1 vial	1	R 57.00	R 65.55
			460	**R 26 220.00**	**R 30 153.00**
			460	**R 26 220.00**	**R 30 153.00**

Valid for 180 days

Employee Signature: _____

Date: 30/7/2020

Approved by: Ehrard van Zyl / Carel Bouwer

EQUITY
PHARMACEUTICALS

30/07/2020

Equity Pharmaceuticals (Pty) Ltd.
1997/009942/07

+27 12 345 1747
+27 12 345 1412
equity@equitypharma.co.za

www.clinigengroup.com
www.equitypharma.co.za

National Department of Health

Directorate: Affordable Medicines

E-mail: Buhle.Mbongo@health.gov.za

Attention: Ms Buhle Mbongo

Dear Ms Mbongo

Re: Request for quotation – Cisplatin 10mg – Section 21 Supply

Trust you are well. Please find below our quotation for *Cisplatin 10mg* supplied under section 21 terms.

- Quantity: **460 vials**
- Delivery Time (Weeks): **2 Weeks after approval**
- Price (Vat Inclusive): **R 65.55 incl. vat**
- Generic Name: **Cisplatin**
- Trade Name: **Platol 10mg**
- Packaging: **1's (singles)**
- Specifications: **10mg**
- Shelf Life: **24 months**
- Package Insert: **Attached**
- Manufacturer: **Venus Remedies**
- Country of Origin: **India**

Please note that the immediate availability of the product is conditioned on the manufacturer receiving notice of our order as soon as possible. Unfortunately, the stock cannot be reserved for our purposes for too long.

We look forward to your response.

Please contact me if you require any additional information.

Kind Regards

Ehrard van Zyl

Size : 155x160mm

during pregnancy.

Women of child bearing age, PLATOL (Cisplatin Injection BP) should be advised to avoid becoming pregnant.

PLATOL (Cisplatin Injection BP) may pass into breast milk and hence breast-feeding while using this drug should be avoided.

UNDESIRABLE EFFECTS:
Toxicities reported to occur infrequently are cardiac abnormalities, hiccups, elevated serum amylase, and rash. Alopecia, malaise, asthenia, and dehydration have been reported as part of post marketing surveillance.

Local soft tissue toxicity has been reported rarely following extravasation of PLATOL. Severity of the local tissue toxicity appears to be related to the concentration of the PLATOL solution. Infusion of solutions with a PLATOL concentration greater than 0.5 mg/mL may result in tissue cellulitis, fibrosis, and necrosis.

OVERDOSAGE AND TREATMENT :
If overdose is suspected, contact poison control center immediately.

Symptoms of overdose may include: nausea, vomiting, deafness.

STORAGE CONDITION
Store below 30°C. Protect from light. Do not freeze. It is recommended that the vial should remain in the carton until the time of use.

DOSAGE FORMS AND PACKAGING AVAILABLE
PLATOL (Cisplatin Injection BP) is available as:
Sterile single dose vial - 10 mg/10 ml, 50 mg/50 ml, 10 mg/20 ml and 50 mg/100 ml

TM - Trademark applied for

Manufactured by:
VENUS REMEDIES LIMITED
Hill Top Industrial Estate, Jharmajri, EPIP
Phase-I (Extn.), Bhatoli Kalan, Baddi,
Distt. Solan, Himachal Pradesh, 173205, India
www.venusremedies.com

℞

VENUS®
Caring Innovations

To be sold by retail on the prescription of Cancer Specialist / Hospitals and Institutions only.

PLATOL
(CISPLATIN INJECTION BP)

NAME AND STRENGTH OF ACTIVE INGREDIENT (S) :

PLATOL 10 mg/10 ml and 50 mg/50 ml
Each ml contains:

Cisplatin	BP	1.0 mg
Sodium Chloride	BP	9.0 mg
Water for Injection	BP	q.s.

PLATOL 10 mg/20 ml and 50 mg/100 ml
Each ml contains:

Cisplatin	BP	0.5 mg
Sodium Chloride	BP	9.0 mg
Water for Injection	BP	q.s.

PRODUCT DESCRIPTION :
Cisplatin is a cytotoxic a platinum coordinating compound containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis-position, with a molecular formula : $PtC_{12}H_6N_2$.

PHARMACODYNAMICS / PHARMACOKINETICS:
Due to its unique chemical structure, the chlorine atoms of cisplatin are more subject to chemical displacement reactions by nucleophiles, such as water or sulfhydryl groups, than to enzyme-catalyzed metabolism. At physiological pH in the presence of 0.1M NaCl, the predominant molecular species are cisplatin and monohydroxymonochloro cis-diammine platinum (II) in nearly equal concentrations. The latter, combined with the possible direct displacement of the chlorine atoms by sulfhydryl groups of amino acids or proteins, accounts for the instability of cisplatin in biological matrices. The ratios of cisplatin to total free (ultrafilterable) platinum in the plasma vary considerably between patients and range from 0.5 to 1.1 after a dose of 100 mg/m^2.

Cisplatin does not undergo the instantaneous and reversible binding to plasma proteins that is characteristic of normal drug-protein binding. However, the platinum from cisplatin, but not cisplatin itself, becomes bound to several plasma proteins, including albumin, transferring, and gamma globulin. Three hours after a bolus injection and two hours after the end of a three hour infusion, 90% of the plasma platinum is protein bound. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.

Size : 155x160mm

Following cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; some what lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration. With the exception of intracerebral tumors, platinum concentrations in tumors are generally somewhat lower than the concentrations in the organ where the tumor is located. Different metastatic sites in the same patient may have different platinum concentrations. Hepatic metastases have the highest platinum concentrations, but these are similar to the platinum concentrations in normal liver. Maximum red blood cell concentrations of platinum are reached within 90 to 150 minutes after a 100 mg/m^2 dose of cisplatin and decline in a biphasic manner with a terminal half-life of 36 to 47 days.

The parent compound, cisplatin, is excreted in the urine and accounts for 13% to 17% of the dose excreted within one hour after administration of 50 mg/m^2. The mean renal clearance of cisplatin exceeds creatinine clearance and is 62 and 50 mL/min/m^2 following administration of 100 mg/m^2 as 2 hour or 6 to 7 hour infusions, respectively.

The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption.

There is a potential for accumulation of ultrafilterable platinum plasma concentrations whenever cisplatin is administered on a daily basis but not when dosed on an intermittent basis.

No significant relationships exist between the renal clearance of either free platinum or cisplatin and creatinine clearance.

Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant.

INDICATIONS :
PLATOL (Cisplatin Injection BP) is used successfully in Metastatic testicular and ovarian carcinoma, advanced bladder cancers, refractory squamous cell neck and head carcinomas.

RECOMMENDED DOSE AND MODE OF ADMINISTRATION
For Testicular tumors: 20 mg/m^2/day for five days (day 1-5) every 3 weeks, for 3 courses.

For Ovarian tumor: 50 mg/m^2/IV once every 3 weeks (day 1).

For Bladder cancer : 50-70 mg/m^2/IV once every 3-4 weeks.

CONTRAINDICATIONS :
PLATOL (Cisplatin Injection BP) is contraindicated in patients with renal impairment.

PLATOL (Cisplatin Injection BP) is also contraindicated in patients with Platinum hypersensitivity.

Patients suffering with hearing disorders should not be given PLATOL (Cisplatin Injection BP) therapy.

WARNINGS AND PRECAUTIONS :
PLATOL (Cisplatin Injection BP) should be administered only under the supervision of a physician who is experienced in the use of cancer chemo-therapeutic agents. The drug can induce severe myelosupression.

Severe local tissue necrosis will occur if there is extravasation during administration. PLATOL (Cisplatin Injection BP) must not be given by the intramuscular or subcutaneous route.

Dosage should be reduced in patients with impaired hepatic function.

Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. Risk factors (active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastenal/pericardial area, previous therapy with other anthracyclines or anthracenedione, concomitant use of other cardiotoxic drugs) may increase the risk of cardiac toxicity. Cardiac toxicity with PLATOL (Cisplatin Injection BP) may occur at lower cumulative doses whether or nit cardiac risk factors are present.

Pediatric patients are at increased risk for developing delayed cardiotoxicity.

PRECAUTIONS
Hypocalccaemia, hypomagnesaemia.

Neurological status should be monitored along with renal status and haematological function.

Proper hydration should be maintained.

INTERACTIONS WITH OTHER MEDICAMENTS
PLATOL (Cisplatin Injection BP) has following interactions:

Aminoglycoside: Nephrotoxicity potentiated by aminoglycoside.

Loop diuretics: Additive ototoxic effect.

Phenytoin: Plasma levels reduced by cisplatin.

Cytotoxic drugs: Increased toxicity when combined with other cytotoxic drugs. Still ideal drug to combine since it causes very little myelosuppression.

5-Fluorouracil & Etoposide: Synergy

Radio protecting agent WR 2721: Efficacy enhanced and toxicity reduced.

PREGNANCY AND LACTATION
PLATOL (Cisplatin Injection BP) is not recommended for use